Hosted on MSN5d
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...
Medscape2d
Immunogenicity and Tolerability of a Heptavalent Pneumococcal Conjugate Vaccine Administered at 3, 5 and 12 Months of Age
GMCs of Anti-Pneumococcal PS Antibodies Reported in This Study, Compared With Those Published for 4-Dose Schedules of PCV Used in Efficacy Trials in Finland (FinOM Trial) and the United States ...
pharmaphorum4d
Vaxcyte's pneumococcal vaccine win points to Prevnar battle
Vaxcyte's new pneumococcal vaccine may only have phase ... which targets 20 common serotypes, but at the highest dose tested generated stronger protection on 18 out of 20 of them – and for ...
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31
Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 ...
PMLiVE7d
Merck’s adult-specific pneumococcal vaccine Capvaxive recommended by CHMP
The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...
Morningstar12d
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
“Invasive pneumococcal disease and pneumococcal pneumonia remain critical public health challenges worldwide,” said Dr. Paula Annunziato, senior vice president, infectious diseases and ...
Medscape15d
Immunogenicity and Tolerability of a Heptavalent Pneumococcal Conjugate Vaccine Administered at 3, 5 and 12 Months of Age
The PCV was well tolerated. Conclusion: The pneumococcal antibody concentrations at 13 months were comparable with those noted previously with the 4-dose schedule. The results suggest that the ...